Angelman syndrome (as)
Drug research and approvals for angelman syndrome (as): what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 16, 2026, 2 studies of angelman syndrome (as) are recruiting on ClinicalTrials.gov, Health Canada has authorized 8 drug trials for it since 2013, and FDA has 0 approved and 13 open orphan designations naming it.
- Recruiting worldwide: 2
- Trials authorized in Canada: 8
- FDA orphan approvals: 0
- EU medicines: 0
Recruiting Now
Newest start dates first, of 2 recruiting on ClinicalTrials.gov ↗- CHAMPION: A Study to Evaluate the Efficacy and Safety of Obudanersen (ION582) in Children and Adults With Angelman…NCT07782827 · Phase 3 · Ionis Pharmaceuticals, Inc. · starts Sep 30, 2026
- A Natural History Study of Angelman SyndromeNCT07417137 · Not reported · Massachusetts General Hospital · starts Sep 9, 2026
Trials Authorized in Canada
Newest first; search them all in Canada trials| May 6, 2026 | Randomized, multi-center, double-blind, sham-controlled, parallel group, phase III clinical study to evaluate the efficacy and safety of intrathecally…RUGONERSEN (OHB-724) | OHB PEDIATRICS LTD. | Pending |
| Oct 29, 2025 | A multi-center, open-label, phase 1/2 trial of the safety and efficacy of mvx-220 gene therapy administered by intra-cisterna magna injection to participants…MVX-220 | MAVRIX BIO, LLC | Pending |
| Mar 19, 2025 | Phase 3 study of the efficacy and safety of ion582 in children and adults with angelman syndromeION582 | Ionis Pharmaceuticals | Ongoing |
| Nov 19, 2024 | A phase 3, randomized, double-blind, sham-controlled study investigating the efficacy and safety of gtx-102 in pediatric subjects with angelman syndromeGTX-102 | Ultragenyx Pharmaceutical Inc. | Closed |
| May 17, 2024 | A long-term extension trial investigating the safety and efficacy of gtx-102 in patients with angelman syndromeGTX-102 | Ultragenyx Pharmaceutical Inc. | Closed |
| Dec 2, 2021 | A study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of intrathecally administered ion582 in patients with angelman syndromeION582 | Ionis Pharmaceuticals | Closed |
| Sep 3, 2020 | An open-label, multicenter study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of ro7248824 in participants with angelman…RO7248824 | Roche | Closed |
| Mar 3, 2020 | A phase 1/2 open-label, multiple-dose, dose-escalating clinical trial of the safety and tolerability of gtx-102 in pediatric patients with angelman syndrome…GTX-102 | Ultragenyx Pharmaceutical Inc. | Closed |
FDA Orphan Designations
Approved first, then open designations, newest first| Oct 16, 2025 | non-replicating recombinant adeno-associated virus serotype…treatment of Angelman syndrome | MavriX Bio, LLC | Designated |
| Jul 3, 2024 | insulin like growth factor 2 receptor ligandtreatment of Angelman syndrome. | New York University | Designated |
| Apr 29, 2024 | 14-species commensal bacterial flora with prebiotics and…treatment of Angelman syndrome | Biom Pharmaceutical Corporation | Designated |
| May 26, 2022 | 2'-O-(2-methoxyethyl) modified antisense oligonucleotide…Treatment of Angelman Syndrome | Ionis Pharmaceuticals, Inc. | Designated |
| Feb 9, 2022 | CannabidiolTreatment of Angelman Syndrome | Benuvia Operations LLC | Designated |
| Mar 22, 2021 | CannabidiolTreatment of Angelman syndrome | Biom Therapeutics | Designated |
| Nov 24, 2020 | UBE3A antisense oligonucleotide with locked nucleic acids…Treatment of Angelman Syndrome | OHB Pediatrics Ltd. | Designated |
| Oct 22, 2020 | Recombinant adeno-associated virus vector containing the…Treatment of Angelman Syndrome | PTC Therapeutics, Inc. | Designated |
| Oct 9, 2019 | cyclo(-L-Glycyl-L-2-Allylproline)Treatment of Angelman syndrome | Neuren Pharmaceuticals, Ltd. | Designated |
| Aug 28, 2019 | Chimeric locked nucleic acid and…Treatment of Angelman syndrome | Ultragenyx Pharmaceutical Inc. | Designated |
| Aug 7, 2018 | [(4-benzylpiperazin-1-yl)(2-(isopentylamino)pyridin-3-yl)met…Treatment of Angelman Syndrome | Seneca Biopharma, Inc. | Designated |
| Sep 6, 2016 | 4,5,6,7-tetrahydroisoxazolo(5,4-c)pyridin-3-olTreatment of Angelman syndrome. | Healx Limited | Designated |
| Oct 29, 2015 | recombinant adeno-associated virus serotype 9 vector…Treatment of Angelman Syndrome. | PTC Therapeutics, Inc. | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA